The fluorescence polarization immunoassay technique has been used previously for the assay of vancomycin and the aminoglycoside antibiotics (gentamicin, tobramycin, and amikacin). We extended this technique to assay streptomycin. Fluorescein-labeled streptomycin was used as the tracer, and antiserum specific for streptomycin was raised in rabbits by conventional procedures. Tracer, sample, and diluted antiserum were combined, and the polarization of tracer fluorescence was determined in a specially designed fluorometer (Abbott TDx). Because of the instrument design, the possibility of fluorescent interferences was eliminated. The coefficient of variation within run was 4% (n = 5), and between run it was 5% (n = 5). We compared the fluorescence polarization immunoassay technique (TDx streptomycin) with a conventional bioassay, using Bacillus subtilis for clinical specimens (n = 39). A least-squares linear regression analysis gave a slope of 1.16, an intercept of 2.41 mg/liter, and a correlation coefficient of 0.885. Repeat analyses by both techniques showed that the largest discrepancies could be explained by the imprecision of the bioassay. Monitoring serum concentrations of antibiotics has been shown to improve patient therapy by providing physicians with an accurate tool for adjusting dosage (4, 8) . Streptomycin was the first aminoglycoside discovered, but its use has been limited by the resistance of many strains of enteric bacteria and by the discovery of newer agents with greater activity. Today, it is used primarily in combination with other antimicrobial agents to treat serious enterococcal infections and tuberculosis. Although streptomycin is less nephrotoxic than other aminoglycosides, patients should have their serum streptomycin concentrations monitored to assure that desired levels are attained and to avoid drug accumulation which might result in ototoxicity and nephrotoxicity. Desirable trough (predose) streptomycin levels are less than 5 mg/liter, and peak levels should be 5 to 20 mg/liter. Toxicity has occurred at streptomycin concentrations greater than 40 to 50 mg/liter (2).
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A variety of methods are available to measure the common aminoglycosides, except streptomycin. For this drug, only bioassay has been widely used in clinical laboratories. We now report the extension of the fluorescence polarization immunoassay (FPIA) technique (5) (6) (7) 9) to the measurement of streptomycin. The reagents for the FPIA for streptomycin were fluo-rescent-labeled streptomycin (tracer) and antibody specific for streptomycin. Fluorescentlabeled streptomycin (tracer) was added to the prediluted serum or plasma sample. Antibody was added, and the fluorescent-labeled streptomycin and streptomycin in the sample competed for binding on the antibody. The competitive binding reation was allowed to equilibrate for 3 min at 35°C, and the fluorescence polarization of the sample was determined. When the tracer was bound to the antibody, the fluorophore was constrained from rotating between the time that light was absorbed and the time that it was emitted. When linearly polarized light was used to excite the tracer, the fluorphore was still highly polarized upon emission. On the other hand, when the tracer was free, its rotation was much greater; molecules were more randomly oriented, and the emitted light was depolarized. Fluorescence polarization, therefore, provides a direct measure of bound and free tracer in a homogeneous competitive binding immunoassay. The precise relationship between the concentration of the unlabeled drug and polarization was established by generating a standard curve. By interpolation between standards, the concentration of the drug in an unknown can be determined.
MATERIALS AND METHODS
Streptomycin was obtained from the U.S. Pharmacopeial Convention, Inc., Rockville, Md. (USP reference standard), and stock solutions were prepared in on October 11, 2017 by guest http://aac.asm.org/ Downloaded from water according to labeled potency. Standards and controls were prepared by diluting a concentrated stock solution into pooled, streptomycin-free normal human serum. The drugs used for cross-reaction studies were from commercial sources.
Fluorescein-labeled streptomycin. Streptomycin tracer was prepared by reacting streptomycin with 5-[(4,6-dichlorotriazin-2-yl)-amino] fluorescein by methods described previously for other drugs (3, 7) . The fluorescein reactant, dissolved in dimethyl sulfoxide, was added to a solution of streptomycin in water, and the pH was adjusted to 9.0 with 0.1 mol of sodium hydroxide per liter. After the reaction mixture had stood for at least 1 h at room temperature, the tracer was isolated by chromatography on DEAE-cellulose, with a sodium-phosphate buffer (0.1 mol/liter; pH 8.A) as the eluant. The fractions containing tracer were identified by UV absorption at 495 nm and by trial assays using antiserum specific for streptomycin. These fractions were combined and diluted to a concentration of about 2 nmol/liter in pH 7.5 phosphate (0.1 mol/liter) buffer containing 0.1 g of bovine gamma globulin per liter and 1.0 g of sodium azide per liter. The tracer was not crystallized, nor was the degree of fluorescein substitution determined. Such characterization would have been difficult because of the minute quantities prepared. Different preparations, however, performed reproducibly. The quantitation of the tracer was based upon an assumption that the streptomycin is substituted with a single fluorescein molecule and has a molar absorbancy of 8 x 104 at 495 nm.
Antiserum. Antiserum was raised in rabbits by conventional methods and diluted in sodium phosphate buffer (0.1 mol/liter; pH 7.5) containing 0.1 g of bovine gamma globulin and 1.0 g of sodium azide per liter.
Immunoassay. The tracer, sample, and diluted antiserum were combined, and the polarization of tracer fluorescence was determined in a specially designed fluorometer (Abbott TDx). The details of this automated instrument have been described previously (6, 9) .
In brief, the instrument determines fluorescence polarization (P) in arbitrary units according to the equation P = (paralel -Iperpcndicular)/(Oparawei + Iperpendicular), where 1 represents light intensity and parallel or perpendicular refers to the plane of polarization. The TDx analyzer subtracts a blank for each sample, which is necessary for the occasional highly icteric specimen. After a predilution step, one half of the final volume of prediluted sample'and one half of the final volume of buffer are combined with a pretreatment reagent, and the parallel and perpendicular fluorescence intensities of the blank are determined. The tracer, antibody, and remainder of the prediluted sample and buffer are then added. After a 3-min incubation, the polarization intensities are again determined, and those of the blank are subtracted to give the net polarization for each sample. The results are calculated based on a standard curve that is stored in a computer memory and are reported directly as the concentration of the drug (milligrams per liter), net polarization (mP, where 1 mP = 0.001 P), and blank intensity (mP).
With each batch of assays, serum controls containing 7.5, 15, and 30 mg of streptomycin per liter were tested concurrently. A run was repeated when any control result was more than 10o (15% for the lowest concentration) in error. A new calibration curve was determined when control results in sequential runs were out of limits.
Bioassay. The bioassay of streptomycin was performed by a published procedure (1) with Bacillus subtilis as the indicator species. The correlation between methods was determined by least-squares linear regression analysis.
RESULTS AND DISCUSSION Standard curve. A typical standard curve for the streptomycin FPIA is shown in Fig. 1 . Because the automated assay was run under strict time and temperature control, it was not necessary to include standards with each run. The standard curve was stored in a computer memory and was stable for at least 14 days.
Precision. The reproducibility of FPIA for streptomycin was determined by supplementing normal human serum samples with those containing clinically significant concentrations of the drug and making five assays on 5 days of five replicates each. The concentration of each replicate was determined from a single standard curve derived from the assay run on the day 1. The means, standard deviations, and coefficients of variation are summarized in Table 1 .
Dilution effects. To assess dilution effects, we diluted five clinical samples by editing the sample volume in the assay protocol and assaying (Table 3) were quantitative from either sample matrix.
Specificity. Cross-reactivity was tested with the following compounds whose chemical structure or concurrent administration could raise the possibility of interference with the streptomycin assay: amikacin, ampicillin, amphotericin B, carbenicillin, cefamandole, cefazolin, cephacetrile, cephalexin, cephaloglycin, cephaloridine, cephalosporin C, cephalothin, chloramphenicol, clindamycin, dibekacin, 3',4'-dideoxykanamycin B, erythromycin, ethacrynic acid, ethambutol, 5-fluorocytosine, fortimicin A, fortimicin B, furosemide, fusidic acid, gentamicin, isoniazid, kanamycin A, kanamycin B, lincomycin, methylprednisolone, methicillin, methotrexate, neomycin, netilmicin, oxytetracycline, penicillin V, penicillin G, prednisolone, rifampin, sagamicin sulfate, seldomycin factor 5, sisomicin, spectinomycin, sulfadiazine, sulfamethoxazole, sulfisoxazole, tetracycline, ticarcillin, tobramycin, (Fig. 2) . The deviation from the unity of the slope of the regression line was investigated by testing the nine standards and controls for the FPIA method by the bioassay. The slope of the regression line for the standards and controls (FPIA = 1.18 bioassay -1.04) was almost identical to that obtained for the clinical specimens. This indicated that differences in calibration were sufficient to explain fully the apparent error in the slope of the regression line calculated for the clinical specimens.
Although the correlation between methods was acceptable to us, we were concerned about the large discrepancies observed with some specimens. For many of these specimens, sufficient serum remained that retesting could be done by both methods. The results of this retesting are given in Table 4 and show that, in general, the FPIA was more reproducible and the variability of the bioassay could account for most of the discrepancies. The apparent bias of FPIA to lower values on the repeated tests may reflect the instability of streptomycin in the samples, which had been stored at -20°C for almost 20 weeks. Streptomycin has been shown to be unstable in serum solutions at elevated temperatures (unpublished data), and aminoglycosides are known to form complexes with Plactam antibiotics which decrease the concentration of the drug as measured by immunoassay. All of the clinical specimens which were examined by a repeat analysis contained penicillin. The FPIA for streptomycin using the TDx instrument is a practical technique for use in the 
